Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: A pooled analysis of Five European Organisation for Research and Treatment of Cancer randomized controlled trials

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2337-2346

  Joosse, Arjen ^a   Collette, Sandra ^b   Suciu, Stefan ^b   Nijsten, Tamar ^a   Patel, Poulam M ^c   Keilholz, Ulrich ^d   Eggermont, Alexander M M ^e   Coebergh, Jan Willem W ^a   De Vries, Esther ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; INTERFERON; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RELAPSE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEX DIFFERENCE; SURVIVAL RATE; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; EUROPE; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; TIME; TUMOR RECURRENCE;

ADULT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84883033569     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.5031     Document Type: Article

References (30)

1. Spatz A, Batist G, Eggermont AM: The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 22:163-168, 2010
2. Micheli A, Ciampichini R, Oberaigner W, et al: The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Eur J Cancer 45:1017-1027, 2009
3. Cook MB, McGlynn KA, Devesa SS, et al: Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev 20:1629-1637, 2011
4. Joosse A, Collette S, Suciu S, et al: Superior outcome of women with stage I/II cutaneous melanoma: Pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 30:2240-2247, 2012
5. Kleeberg UR, Suciu S, Bröcker EB, et al: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness 3 mm) or regional lymph node metastasis. Eur J Cancer 40:390-402, 2004
6. Eggermont AM, Suciu S, MacKie R, et al: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366:1189-1196, 2005
7. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008
8. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755, 2005
9. Patel PM, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476-1483, 2011
10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
11. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
12. Punt CJ, Buyse M, Köhne CH, et al: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998-1003, 2007
13. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
14. Xing Y, Chang GJ, Hu CY, et al: Conditional survival estimates improve over time for patients with advanced melanoma: Results from a population-based analysis. Cancer 116:2234-2241, 2010
15. Balch CM, Gershenwald JE, Soong SJ, et al: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452-2459, 2010
16. Joosse A, de Vries E, Eckel R, et al: Gender differences in melanoma survival: Female patients have a decreased risk of metastasis. J Invest Dermatol 131:719-726, 2011
17. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al: Prognosis in patients with sentinel node–positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206-2214, 2011
18. Martinez SR, Tseng WH, Young SE: Outcomes for lymph node-positive cutaneous melanoma over two decades. World J Surg 35:1567-1572, 2011
19. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
20. Wasif N, Bagaria SP, Ray P, et al: Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 104:111-115, 2011
21. Unger JM, Flaherty LE, Liu PY, et al: Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 91:1148-1155, 2001
22. de Vries E, Nijsten TE, Visser O, et al: Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 19:583-589, 2008
23. Mervic L, Leiter U, Meier F, et al: Sex differences in survival of cutaneous melanoma are age dependent: An analysis of 7338 patients. Melanoma Res 21:244-252, 2011
24. Joosse A, De Vries E, van Eijck CH, et al: Reactive oxygen species and melanoma: An explanation for gender differences in survival? Pigment Cell Melanoma Res 23:352-364, 2010
25. de Giorgi V, Gori A, Grazzini M, et al: Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther 11:739-747, 2011
26. Bouman A, Heineman MJ, Faas MM: Sex hormones and the immune response in humans. Hum Reprod Update 11:411-423, 2005
27. Chen W, Mempel M, Traidl-Hofmann C, et al: Gender aspects in skin diseases. J Eur Acad Dermatol Venereol 24:1378-1385, 2010
28. Correale J, Ysrraelit MC, Gaitán MI: Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 185:4948-4958, 2010
29. Field S, Newton-Bishop JA: Melanoma and vitamin D. Mol Oncol 5:197-214, 2011
30. Morvillo V, Lüthy IA, Bravo AI, et al: Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases. Melanoma Res 12:529-538, 2002